Tumor-selective CTLA-4 antagonists
US10414814B2 · kind B2 · utility
2Cited by
22References
5Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jul 2, 2015 |
| Grant date | Sep 17, 2019 |
| Priority date | — |
| Expiry date | Aug 29, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/50
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
Provided herein are recombinant masking proteins and recombinant ligand proteins useful in treating cancer, neurodegenerative disease, and cardiovascular disease. The recombinant masking proteins provided herein may, inter alia, be used as non-covalent masks of antagonists of, for example, cellular growth factors (e.g., TNF) or cell surface proteins (e.g., CTLA-4).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.